Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer

Phase II Study of Sorafenib in Combination With Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: ECOG 5203

(2010) Weijing Sun et al.   JOURNAL OF CLINICAL ONCOLOGY

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial

(2009) Y.-K. Kang et al.   ANNALS OF ONCOLOGY

Hemostatic complications of angiogenesis inhibitors in cancer patients

(2008) Francesca Elice et al.   AMERICAN JOURNAL OF HEMATOLOGY

Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction

(2008) M. Dank et al.   ANNALS OF ONCOLOGY

A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel

(2008) K. T. Flaherty et al.   CLINICAL CANCER RESEARCH

Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma

(2008) F.C.S. Eng et al.   EJSO

Bowel Perforation After Radiotherapy in a Patient Receiving Sorafenib

(2008) Natascha A.J.B. Peters et al.   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer

(2008) David Cunningham et al.   NEW ENGLAND JOURNAL OF MEDICINE